A comparative study to evaluate the efficacy and safety of Vildagliptin as an add-on therapy to a low-dose Metformin vs an uptitration of Metformin in type 2 DM patients

International Journal of Pharmaceutical Sciences Review and Research

Volumn 22, Issue 2, 2013, Pages 116-120

  Bhandare, Basavaraj ^a   Satyanarayana, V ^a   Adhikary, Jyotirmoy ^a  

^a Periyar EVR   (India)

Author keywords

HbA1c; Metformin; T2DM; Vildagliptin

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STUDENT T TEST; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 84884961627     PISSN: 0976044X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Waly Mostafa et al., The global burden of Type 2 diabetes: A review, Int J Biol Med Res, 1(4), 2010, 326-329.
2. Vijayakumar G, High Prevalence of Type 2 Diabetes Mellitus and Other Metabolic Disorders in Rural Central Kerala, JAPI, 5, 2009, 563-567.
3. Dejager S, Schweizer Anja, Minimizing the Risk of Hypoglycemia with Vildagliptin: Clinical Experience, Mechanistic Basis, and Importance in Type 2 Diabetes Management, Diabetes Ther, 2(2), 2011, 51-66.
4. Hayat AS, Shaikh N et al., Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus, World Applied Sciences Journal, 7(1), 2009, 01-06.
5. Goodarzi MO, Bryer-Ash M, Metformin revisited: reevaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents, Diabetes Obes Metab, 7, 2005, 654-665.
6. Filozof C, Schwartz S, Foley JE, Effect of vildagliptin as add-on therapy to a low-dose Metformin, World J Diabetes, 1(1), 2010, 19-26.
7. Dunning BE, Ligueros-Saylan M, D'Alessio DA, Balas B, Kelley DE, Deacon CF, Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metform in treated patients with type 2 diabetes, Diabetologia, 49, 2006, 110-111.
8. Bohannon N, Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice, Postgraduate Medicine, 121 (1), 2009, 1-6. Available from internet http://www.sugarnancy.com/articles/ovwgliptinclass.pdf
9. Kalra S, Emerging Role of Dipeptidyl Peptidase-IV (DPP-4) Inhibitor Vildagliptin in the Management of Type 2 Diabetes, JAPI, 59, 2011, 237-245.
10. Nauck MA, Meier JJ, Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes, 124, 2005, 135-48.
11. Drucker DJ, Enhancing Incretin Action for the Treatment of Type 2 Diabetes, Diabetes Care, 26, 2003, 2929-2940.
12. Ahrén B, Exenatide: a novel treatment of type 2 diabetes, Therapy, 2, 2005, 207-222.
13. Ahren B, Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties, Expert Opin Investig Drugs, 15, 2006, 431-42.
14. Bosi E, Dotta F, Jia Y, Goodman M, Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus, Diabetes Obes Metab, 11, 2009, 506-515.
15. Gill GV, Woodward A, Casson IF, Weston PJ, Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes-the 'dead in bed' syndrome revisited, Diabetologia, 52, 2009, 42-45.
16. Campbell I, Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia, Diabet Med, 8, 1991, 3-4.
17. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V, Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring, Diabetes Care, 26, 2003, 1485-1489.
18. Dandona P, Chaudhuri A, Dhindsa S, Proinflammatory and prothrombotic effects of hypoglycemia, Diabetes Care, 33, 2010, 1686-1687.
19. UK Hypoglycaemia Study Group, Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration, Diabetologia, 50, 2007, 1140-1147.
20. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D, Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France, Diabetes Obes Metab, 10(1), 2008, 16-24.
21. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE, Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes, J Clin Endocrinol Metab, 94, 2009, 1236-43.
22. Scherbaum WA, Schweizer A, Mari A et al., Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia, Diabetes Obes Metab, 10, 2008, 675-682.
23. Rosenstock J, Foley JE, Rendell M et al., Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function and postprandial glycemia in subjects with impaired glucose tolerance, Diabetes Care, 31, 2008, 30-35.
24. Masoudi FA, Wang Y, Inzucchi SE, et al., Metformin and thiazolidinedione use in Medicare patients with heart failure, JAMA, 290, 2003, 81-85.
25. Neumiller JJ, Wood L, Campbell RK, Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus, Pharmacotherapy, 30(5), 2010, 463-84.
26. Rosenstock J, Fitchet M, Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes, Int J Clin Pract Suppl, 159, 2008, 15-23.
27. Davidson JA, Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors, Cleve Clin J Med, 76(5), 2009, S28-38.
28. Schweizer A, Dejager S, Foley JE, Kothny W, Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies, Vasc Health Risk Manag, 7, 2011, 49-57.
29. Bolli G, Dotta F et al., Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study, Diabetes Obes Metab, 10(1), 2008, 82-90.
30. Scheen AJ, Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes, Rev Med Liege, 62, 2007, 217-221.
31. Del Prato S, Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes, Int J Clin Pract Suppl, 154, 2007, 38-48.
32. Bailey CJ, Turner RC, Metformin, N Engl J Med, 334, 1996, 574-579.